Clinical and urodynamic effects of norfenefrine in women with stress incontinence.
20 women with stress incontinence were treated with an alpha-adrenoceptor stimulating agent norfenefrine (Nevadral Retard) for 3 months. The mean dose administered was 60 mg given in slow-release tablets. Significant beneficial effect on the symptom and the 'sign' of stress incontinence was found as well as a significant increase in the maximum urethral closure pressure. 7 patients (35%) became subjectively and objectively continent. Only minor side effects were observed during treatment.
D015078:2-Hydroxyphenethylamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009655:Octopamine / Q000031:analogs & derivatives*; D010627:Phenethylamines / Q000627:therapeutic use*; D014521:Urethra / Q000503:physiopathology; D014550:Urinary Incontinence, Stress / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics
D000316:Adrenergic alpha-Agonists; D003692:Delayed-Action Preparations; D010627:Phenethylamines; D009655:Octopamine; D015078:2-Hydroxyphenethylamine; C005310:norfenefrine